期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

17-AAG及其衍生物治疗肺癌研究进展

Advances in 17-allylamino-17-demethoxygeldanamycin and its derivatives in lung cancer
原文传递
导出
摘要 17-丙烯胺基-17-去甲氧基格尔德霉素（17-AAG）及衍生物17-AAGH2、17-DMAG是热休克蛋白90竞争性抑制剂，能够降解多条信号传导通路关键蛋白，抑制肿瘤细胞生长，促使凋亡。临床Ⅰ-Ⅱ期研究证明，17-AAG及衍生物能够抑制T790M表达类型肺癌细胞，抑制肺癌细胞表皮生长因子受体，协同化疗药物细胞毒性、放射增敏作用。 17-allylamino- 17-demethoxygeldanamycin（17-AAG） as well as its derivatives 17-AAGH2 and 17-DMAG are heat shock protein90 inhibitor. It can lead to the depletion of oncogenie client proteins which play key roles in several signal transductions pathways. Cell growth is inhibited and apoptosis is predicated. Clinical phase Ⅰ and phase Ⅱ trials indicate 17-AAG and its derivatives can efficiently inhibit lung cancer cells expressing T790M and epidermal growth ＇factor, coordinate with chemotherapeutics cytotoxicity and increase radiosensitizing effect.
作者 吴清华(综述) 刘璐(审校)
机构地区 东南大学临床医学院核技术研究所
出处 《国际肿瘤学杂志》 CAS 2009年第8期601-604,共4页 Journal of International Oncology
基金 基金项目：国家自然科学基金资助项目（30470500）
关键词 肿瘤 17-丙烯胺基-17-去甲氧基格尔德霉素 药物疗法 Neoplasm 17- allylamino- 17- demethoxygeldanamycin Drug therapy
分类号 R730.54 [医药卫生—肿瘤] R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Senju M, Sueoka N, Sato A, et al. Hsp90 inhibitors cause G2-M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol, 2006, 132(2) :150-158.
  • 2Miyata Y. HsP90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curt Pharm Des, 2005, 11 (9) : 1131-1138.
  • 3Ge J, Normanl E, Porler JR, et al. Design, syntbesis and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem, 2006, 49 ( 15 ) :4606-4615.
  • 4Price JT, Quinn JM, Sims NA, et al. The heat shock Protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamyein, enhances osteoelast formation and potenriates bone metastasis of a human breast cancer cell line. Cancer Res, 2005, 65( 11 ) :4929-4938.
  • 5Sbintani S, Zhang T, Aslam A, et al. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines. Int J Oneol, 2006, 29(5) :1111-1117.
  • 6Guo W, Reigan P, Siegel D, et al. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P) H: quinone oxidoreduetase 1 : Role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res, 2005, 65 (21) : 10006-10015.
  • 7Maroney AC, Marugan JJ, Mezzasalma TM, et al. Dihydroquinone ansamycins : Toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. Biochemistry, 2006, 45(17) :5678-5685.
  • 8Guo W, Siegel D, Ross D. Stability of the Hsp90 Inhibitor 17AAG Hydroquinone and Prevention of Metal-Catalyzed Oxidation. J Pharm Sei, 2008, 97(12) :5147-5157.
  • 9Hollingshead M, Alley M, Burger AM, et al. In vivo antitumor efficacy of 17- DMAG ( 17- dimethylaminoethylamino- 17- demethoxygeldanamycin hydrochloride), a water-soluble geldanamyein derivative. Cancer Chemother Pharmacol, 2005, 56 (2) : 115-125.
  • 10Gossett DR, Bradley MS, Jin X, et al. 17-Allyamino-17-demethoxygeldanamycin and 17- N, N- dimethyl ethylene diamine- geldanamytin have cytotoxic activity against multiple gynecologic cancer cell types. Gynecol Oncol, 2005, 96(2) :381-388.
国际肿瘤学杂志
2009年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部